Quick Answer
Metagenomi Therapeutics, Inc. reported Stockholders Equity of $158.60 million for fiscal year 2025.
Metagenomi Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $158.60M | -32.5% |
| 2024 | $234.86M | +273.2% |
| 2023 | -$135.58M | -82.2% |
| 2022 | -$74.43M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $178.45M | -30.2% | -8.9% |
| June 30, 2025 | $195.83M | -27.3% | -7.9% |
| March 31, 2025 | $212.66M | -22.8% | -9.5% |
| December 31, 2024 | $234.86M | +273.2% | -8.2% |
| September 30, 2024 | $255.77M | +214997.4% | -5.1% |
| June 30, 2024 | $269.42M | +362.7% | -2.3% |
| March 31, 2024 | $275.63M | +406.2% | +303.3% |
| December 31, 2023 | -$135.58M | -82.2% | -113816.0% |
- Metagenomi Therapeutics, Inc. showed a decrease of -32.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Metagenomi Therapeutics, Inc.’s stockholders equity has grown by 313.1% (from -$74.43 million to $158.60 million).
- The most recent figure is from Metagenomi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: